Solid Biosciences’ Post

The Solid team is headed back to Orlando this week to engage with the Duchenne community at Parent Project Muscular Dystrophy’s 30th Annual Conference, June 27-29. At the conference, our Chief Medical Officer, Gabriel Brooks, M.D., will participate in an industry panel “Research Row: Gene Therapy – Current and Evolving Landscape Session” on Friday, June 28, 1:45 p.m. to share insights about gene therapy and INSPIRE DUCHENNE, Solid’s first-in human clinical study evaluating SGT-003. We look forward to engaging with the Duchenne community in Orlando! For more information, visit: https://lnkd.in/gMhB4CUA  #GeneTherapy #DuchenneMuscularDystrophy #PPMD30

Solid is thrilled to sponsor Parent Project Muscular Dystrophy’s 30th Annual Conference in Orlando, Florida, June 27-29 that aims to empower, educate and unite patients with Duchenne and their families. We are proud to continue our steadfast support of PPMD’s efforts to support the Duchenne community and are grateful for their efforts.   For more information: https://lnkd.in/gMhB4CUA   #GeneTherapy #DuchenneMuscularDystrophy #PPMD30

Aligning with our commitment to ensuring patient perspective is incorporated in our work. We are honored to be a sponsor of an Externally-Led Patient Focused Drug Development Meeting, organized by The SADS Foundation. Scheduled for June 11, this meeting, will collect important information to help ensure scientific and clinical pursuits address unmet needs of patients with rare cardiac conditions, as well as their caregivers and families.   Learn more: https://lnkd.in/gwqUWYQG    #CPVT #PatientFocusedDrugDevelopment

Our Chief Medical Officer, Gabriel Brooks, M.D., will be participating in the industry panel livestream at the upcoming Hearts in Rhythm Organization Symposium 2024 on June 7, at 2:30 PM ET.    Join to hear Dr. Brooks discuss innovative approaches to combating inherited cardiac diseases through gene therapy.    Learn more at: https://lnkd.in/e7_vxJzN   #HiROSymposium #GeneTherapies #CardiacDisease

Solid is headed to Orlando, Florida this weekend as a proud sponsor of @CureDuchenne’s FUTURES 2024 National Conference. Our Senior Director, Clinical Sciences, Patrick Gonzalez, Ph.D., will be participating in the Scientific session “Gene Therapy Approaches to Treatment” on Friday, May 24, 10 a.m., to share insights about gene therapy and INSPIRE DUCHENNE, Solid’s first-in human clinical study evaluating SGT-003. For more information on the conference, visit: https://lnkd.in/gn5vHUnn #LetsCureDuchenne #CureDuchenne #2024FUTURES #WeWILLCureDuchenne

We are looking forward to engaging with the Duchenne community at the annual CureDuchenne FUTURES National Conference, which brings education, connection, and hope to patients with Duchenne and their families. As a proud sponsor, we are thrilled to support the important efforts of CureDuchenne and help support those impacted by Duchenne. For more information on the conference, visit: https://lnkd.in/gn5vHUnn #LetsCureDuchenne #CureDuchenne #2024FUTURES #WeWILLCureDuchenne

Solid Biosciences today reported Q1 2024 financial results and provided a business update. Read the full release: https://lnkd.in/ebaYjftG

Are you attending #ASGCT2024? Don’t miss our Senior Principal Scientist, E Xiaofei present “Novel Mechanism to Increase AAV Yield through Blocking AAV Transduction of Manufacturing HEK293 Cells During AAV Production” during session “AAV Manufacturing I.” Join us for the oral presentation at 2:15-2:30 PM ET, Ballroom 3. Learn more: https://lnkd.in/gSjPsVn  American Society of Gene & Cell Therapy #CellTherapy #GeneTherapy #ASGCT